Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

Study Identifier:

417-201-00012

ClinicalTrials.gov Identifier:

NCT05248659

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Recruiting

Subscribe to Updates

Study Details

Medical Condition

Autoimmune Disease

Study Drug

Drug: Sibeprenlimab 400 mg s.c. Q4weeks

Date

Apr 2022 - Dec 2028

Patient Requirements

Sex: Female & Male

Age: 18+ years

Requirements Information

Protocol Summary

This is a phase 2/3 open-label trial to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

New York, New York, United States, 10001

Status

N/A